Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOASH T LAZARUS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1720374754
CMS profile
1067400
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$88,983.81

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $24,153.62 22
Allergan, Inc. $21,575.71 36
Acorda Therapeutics, Inc $12,349.08 15
Celgene Corporation $11,966.67 9
Neurocrine Biosciences, Inc. $7,211.75 6
ACADIA Pharmaceuticals Inc $4,800.00 2
US WorldMeds, LLC $3,545.96 4
GENZYME CORPORATION $1,830.00 1
EMD Serono, Inc. $1,337.38 5
SANOFI-AVENTIS U.S. LLC $90.99 1
Teva Pharmaceuticals USA, Inc. $77.07 1
Avanir Pharmaceuticals, Inc. $18.28 1
Amneal Pharmaceuticals LLC $15.48 1
Amgen Inc. $11.82 1

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOASH T LAZARUS

NPI 1720374754 · CMS profile ID 1067400

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720374754?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOASH T LAZARUS, NPI 1720374754, CMS profile ID 1067400. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720374754?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOASH T LAZARUS, NPI 1720374754, CMS profile ID 1067400. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720374754?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOASH T LAZARUS, NPI 1720374754, CMS profile ID 1067400, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1720374754?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $88,983.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Acorda Therapeutics, Inc $770.0003/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700463 CMS
Neurocrine Biosciences, Inc. $3,603.0003/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748928879 CMS
Allergan, Inc. $1,920.0003/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468119 CMS
Allergan, Inc. $20.2303/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468121 CMS
ACADIA Pharmaceuticals Inc $2,800.0003/02/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748567669 CMS
Allergan, Inc. $3.7903/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468117 CMS
Teva Pharmaceuticals USA, Inc. $77.0702/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749507427 CMS
Acorda Therapeutics, Inc $458.6002/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700459 CMS
Acorda Therapeutics, Inc $281.3702/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700461 CMS
Allergan, Inc. $2.4802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468115 CMS
US WorldMeds, LLC $1,500.0002/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749602945 CMS
Celgene Corporation $46.0602/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727887589 CMS
Celgene Corporation $29.7002/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727887591 CMS
Celgene Corporation $59.9902/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727887595 CMS
Celgene Corporation $50.9202/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727887597 CMS
Celgene Corporation $4,650.0002/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727887635 CMS
US WorldMeds, LLC $45.9602/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749602941 CMS
US WorldMeds, LLC $1,500.0002/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749602949 CMS
Biogen, Inc. $3,150.0002/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264553 CMS
Biogen, Inc. $125.0002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264565 CMS
Acorda Therapeutics, Inc $2,900.0002/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700457 CMS
Biogen, Inc. $3,600.0001/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264549 CMS
Biogen, Inc. $58.6501/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264551 CMS
Biogen, Inc. $122.5601/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264563 CMS
Acorda Therapeutics, Inc $66.3001/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700445 CMS
Acorda Therapeutics, Inc $32.4801/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700447 CMS
Acorda Therapeutics, Inc $93.3701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700449 CMS
Acorda Therapeutics, Inc $29.7701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700451 CMS
Acorda Therapeutics, Inc $72.2001/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700453 CMS
Acorda Therapeutics, Inc $124.9901/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716700455 CMS
Allergan, Inc. $161.2201/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468101 CMS
Allergan, Inc. $93.2801/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468103 CMS
Allergan, Inc. $50.2401/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468105 CMS
Allergan, Inc. $556.6001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468107 CMS
Allergan, Inc. $40.2101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468109 CMS
Allergan, Inc. $3,500.0001/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468111 CMS
Allergan, Inc. $150.9201/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468113 CMS
Allergan, Inc. $124.4201/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468099 CMS
Allergan, Inc. $5.0301/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723468097 CMS
SANOFI-AVENTIS U.S. LLC $90.9901/22/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744092437 CMS
Biogen, Inc. $5.7001/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264567 CMS
EMD Serono, Inc. $24.8301/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751265993 CMS
Amneal Pharmaceuticals LLC $15.4801/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719985321 CMS
Biogen, Inc. $425.4401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264571 CMS
Biogen, Inc. $72.0001/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264573 CMS
Biogen, Inc. $8,663.0001/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264575 CMS
Biogen, Inc. $36.1401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264579 CMS
Biogen, Inc. $58.9301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264587 CMS
Biogen, Inc. $71.9501/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264589 CMS
Biogen, Inc. $89.2101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737264591 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140,264.71 220
PY2020 $88,983.81 105
PY2021 $158,338.43 138
PY2022 $177,955.51 208
PY2023 $163,809.89 312
PY2024 $195,068.95 302
PY2025 $167,324.75 231

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $121,278.29 22
PY2024 Principal investigator $110,083.79 29
PY2023 Principal investigator $21,580.00 6
PY2022 Principal investigator $16,650.00 1
PY2019 Recipient $7,000.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $2,800.00 11/30/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199377
Principal investigator 1 TG Therapeutics, Inc. $3,950.00 07/31/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199359
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574239
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574242
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574246
Principal investigator 1 F. Hoffmann-La Roche AG $7,181.00 06/20/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574229
Principal investigator 1 TG Therapeutics, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199291
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/07/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199289
Principal investigator 1 TG Therapeutics, Inc. $3,725.00 05/01/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199283
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 04/25/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574235
Principal investigator 1 TG Therapeutics, Inc. $175.00 04/11/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199285
Principal investigator 1 TG Therapeutics, Inc. $750.00 04/11/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199287
Principal investigator 1 TG Therapeutics, Inc. $1,100.00 03/31/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199281
Principal investigator 1 TG Therapeutics, Inc. $2,700.00 02/28/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199279
Principal investigator 1 TG Therapeutics, Inc. $5,075.65 02/28/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199333
Principal investigator 1 Novartis Pharmaceuticals Corporation $73,749.14 02/26/2025 Non-covered Recipient Entity
ATLANTA NEUROSCIENCE INSTITUTE
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190305063
Principal investigator 1 TG Therapeutics, Inc. $4,325.00 02/01/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199277
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,372.50 01/22/2025 Non-covered Recipient Entity
ATLANTA NEUROSCIENCE INSTITUTE
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185547314
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574214
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574218
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 01/22/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211574224
Principal investigator 1 TG Therapeutics, Inc. $7,350.00 01/06/2025 Non-covered Recipient Entity
Atlanta Neuroscience Institute, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199275